-$0.75 Earnings Per Share Expected for Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) This Quarter

Wall Street analysts expect Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPIGet Rating) to post ($0.75) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Checkmate Pharmaceuticals’ earnings. Checkmate Pharmaceuticals posted earnings of ($0.88) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 14.8%. The firm is scheduled to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Checkmate Pharmaceuticals will report full year earnings of ($3.15) per share for the current fiscal year, with EPS estimates ranging from ($3.24) to ($3.05). For the next financial year, analysts expect that the firm will post earnings of ($2.83) per share, with EPS estimates ranging from ($4.11) to ($1.55). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover Checkmate Pharmaceuticals.

Checkmate Pharmaceuticals (NASDAQ:CMPIGet Rating) last posted its earnings results on Tuesday, March 29th. The company reported ($0.62) earnings per share (EPS) for the quarter.

CMPI has been the subject of several research reports. BTIG Research cut Checkmate Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, April 20th. Zacks Investment Research raised Checkmate Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, May 26th.

CMPI remained flat at $$10.50 during trading hours on Thursday. Checkmate Pharmaceuticals has a 1-year low of $2.00 and a 1-year high of $10.50. The firm’s 50 day moving average is $8.60 and its 200-day moving average is $4.95. The stock has a market capitalization of $231.40 million, a price-to-earnings ratio of -3.60 and a beta of -4.81.

In other news, major shareholder Global Strategic Fund I. Venbio sold 17,600 shares of the company’s stock in a transaction that occurred on Monday, May 9th. The stock was sold at an average price of $10.37, for a total transaction of $182,512.00. Following the transaction, the insider now directly owns 2,448,481 shares of the company’s stock, valued at $25,390,747.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Global Strategic Fund I. Venbio sold 399,923 shares of the company’s stock in a transaction on Tuesday, April 19th. The stock was sold at an average price of $10.42, for a total value of $4,167,197.66. Following the sale, the insider now owns 3,273,451 shares of the company’s stock, valued at approximately $34,109,359.42. The disclosure for this sale can be found here. Insiders have sold a total of 1,012,901 shares of company stock valued at $10,538,367 over the last ninety days. Company insiders own 62.60% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC bought a new position in shares of Checkmate Pharmaceuticals in the fourth quarter worth about $31,000. BlackRock Inc. raised its position in Checkmate Pharmaceuticals by 126.7% during the third quarter. BlackRock Inc. now owns 51,794 shares of the company’s stock valued at $205,000 after purchasing an additional 28,944 shares during the period. Finally, Decheng Capital Management III Cayman LLC bought a new position in shares of Checkmate Pharmaceuticals during the first quarter valued at approximately $4,253,000. Institutional investors own 74.56% of the company’s stock.

Checkmate Pharmaceuticals Company Profile (Get Rating)

Checkmate Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma.

Recommended Stories

Get a free copy of the Zacks research report on Checkmate Pharmaceuticals (CMPI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Checkmate Pharmaceuticals (NASDAQ:CMPI)

Want More Great Investing Ideas?

Receive News & Ratings for Checkmate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkmate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.